Anthony Walko
Adult Health · Westwood, NJNPI 1710420476
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,658 of the $34,188 with a category attached, or 69.2%. Gilead accounts for 70.0% of it on its own, with 9 other manufacturers making up the rest. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $201.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$24K
- Viiv Healthcare Company$9K
- Phathom Pharmaceuticals, Inc.$218
- Theratechnologies Inc.$161
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$143
- Novo Nordisk$125
- plus $209 from 4 others
What the payments were for
- Consulting fees$1,8605%
- Speaking & faculty fees$23,65869%
- Travel & lodging$4,02312%
- Food & beverage$4,64814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 115 | $23,947 |
| Viiv Healthcare Company | 32 | $9,386 |
| Phathom Pharmaceuticals, Inc. | 3 | $218 |
| Theratechnologies Inc. | 4 | $161 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $143 |
| Novo Nordisk | 1 | $125 |
| AbbVie | 7 | $114 |
| Merck | 3 | $56 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,188 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 25 | $586,948 |
| DescovyEmtricitabine/Tenofov Alafenam | 67 | $143,730 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $50,004 |
| DovatoDolutegravir Sodium/Lamivudine | 14 | $41,892 |
| Doxycycline Hyclate | 16 | $537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Descovy, Biktarvy | $23,947 | $780,682105 claims |
| Viiv Healthcare CompanyDovato | $9,386 | $41,89214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Westwood
- June HalperHackensack$358K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Phyllis DudaCamden$46K
- Samantha DepadovaHackensack$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.